GLP-1 on Medicaid: Does Medicaid Cover Wegovy, Ozempic & Zepbound?

Does Medicaid cover GLP-1 medications?

Medicaid coverage for GLP-1 receptor agonists is one of the most confusing topics in weight loss healthcare. The short answer: it depends entirely on your state. Unlike Medicare, which has federal standards, Medicaid is administered at the state level, meaning coverage policies, formularies, and prior authorization requirements vary dramatically across all 50 states and Washington D.C.

As of 2026, the landscape is evolving rapidly. More states are adding GLP-1 coverage as the medications prove their long-term cost-effectiveness, but the majority still restrict coverage to type 2 diabetes indications only.

State-by-state Medicaid GLP-1 coverage (2026)

The following table summarizes Medicaid coverage for GLP-1 weight loss medications (Wegovy, Zepbound) as of September 2026. This data is updated regularly but you should always verify with your state Medicaid office.

Note: This table reflects our best understanding as of September 2026. Medicaid formularies change frequently. Always verify with your state Medicaid office or pharmacy.

Medicaid eligibility criteria for GLP-1 coverage

Even in states that cover GLP-1 weight loss medications, you must meet specific criteria:

• BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity like hypertension, type 2 diabetes, or sleep apnea)
• Documented lifestyle intervention — Most states require 3-6 months of documented diet and exercise program participation
• Age 18+ (some states cover adolescents 12+ with special criteria)
• No contraindications — Personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
• Prior authorization — Your provider must submit a form justifying medical necessity

How to get prior authorization for GLP-1 on Medicaid

Prior authorization (prior auth) is the process where your healthcare provider must get approval from Medicaid before the medication will be covered. Here is what your provider needs to submit:

1. Letter of medical necessity — Documenting BMI, comorbidities, and why GLP-1 is medically necessary
2. Lifestyle intervention documentation — Records showing 3-6 months of diet/exercise program participation
3. Previous medication trials — Documentation of failed or contraindicated alternatives (phentermine, orlistat, etc.)
4. Treatment plan — Dosing schedule, monitoring plan, and weight loss goals
5. Contraindication screening — Confirmation no personal/family history of MTC or MEN 2

The prior auth process typically takes 1-2 weeks. If approved, coverage is usually granted for 6-12 months, after which reauthorization is required with documentation of progress.

What to do if Medicaid denies your GLP-1

Denial is common, especially in states without explicit weight loss coverage. You have options:

1. File an appeal

You have the right to appeal any Medicaid denial. Appeals must be filed within 30-90 days depending on your state. Your provider can write a stronger letter of medical necessity, and you can include documentation of comorbidities that make weight loss medically necessary.

2. Check manufacturer patient assistance programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer patient assistance programs that provide medications for as low as $0-$25/month for eligible patients. Eligibility is typically based on income, not insurance type.

• Novo Nordisk Patient Assistance Program — Wegovy may be free for patients earning up to 400% of the federal poverty level
• Eli Lilly Patient Assistance Program — Zepbound may be free for eligible low-income patients

3. Compounded semaglutide — the best alternative

If Medicaid denies coverage, compounded semaglutide is available from $147/month through telehealth providers — no insurance needed, no prior authorization. This is the same active ingredient as Wegovy/Ozempic, produced by FDA-regulated compounding pharmacies.

4. Medicaid managed care plans

If you are on a Medicaid managed care plan (like Molina, Centene, or UnitedHealthcare Community Plan), check with your specific plan. Some managed care organizations have more generous GLP-1 coverage than the state Medicaid fee-for-service program.

Medicaid vs Medicare for GLP-1 coverage

Medicare Part D covers GLP-1 medications for FDA-approved indications, but coverage for weight loss specifically (Wegovy, Zepbound) has been historically restricted. However, as of 2026, Medicare has expanded coverage for anti-obesity medications following the SELECT trial showing cardiovascular benefits. Medicaid is generally more restrictive than Medicare for weight loss GLP-1s.

The bottom line

Medicaid coverage for GLP-1 weight loss medications is improving but still limited. If your state does not cover GLP-1s for weight loss, compounded semaglutide from $147/month is the most accessible and affordable alternative. No insurance, no prior auth, no waiting.

References

• Kaiser Family Foundation. "Medicaid Coverage of Obesity Screening and Treatment Services." 2026 Report.
• CMS. "Medicaid Drug Rebate Program and GLP-1 Formulary Status." 2026.
• Novo Nordisk Patient Assistance Program. Accessed September 2026.
• Eli Lilly Patient Assistance Program. Accessed September 2026.
• American Society of Health-System Pharmacists. "State Medicaid GLP-1 Formulary Review." 2026.
• SELECT Trial Investigators. "Semaglutide and Cardiovascular Outcomes in Obesity." NEJM 2024. PMID: 38438311